“聪明药”使用率上升 美国**

2018-07-10 佚名 新华网

研究人员日前在《国际药物政策杂志》上发表报告说,对全球近3万人的调查发现,使用俗称“聪明药”的利他林等药物来增强认知表现的人数呈上升趋势,其中美国人的使用率最高。


究人员日前在《国际药物政策杂志》上发表报告说,对全球近3万人的调查发现,使用俗称“聪明药”的利他林等药物来增强认知表现的人数呈上升趋势,其中美国人的使用率最高。

利他林属于中枢神经兴奋剂,对大脑皮质和皮质下中枢有兴奋作用,有助振奋精神、缓解抑郁以及减轻疲乏,常用于治疗多动症,但近年来一些健康人也服用此类药物来增强记忆力或注意力。英国医疗保健监管机构曾警告滥用这类药物的风险。

新调查主要针对利他林和阿德拉等用于治疗多动症的处方药和治疗睡眠紊乱的处方药莫达非尼等。结果显示,“聪明药”的使用率在调查所涉及的15个国家和地区都有上升。

其中,美国人的使用率居首,2017年有30%的受访者在过去一年中至少使用过一次这种药物,而这一比例在2015年是20%。而欧洲地区增幅最大,从2015年的3%激增到2017年的16%,其中英国使用者从2015年的5%增长到2017年的23%。

负责这项研究的美国加利福尼亚大学旧金山分校教授拉丽萨·梅尔表示,虽然这一问卷调查的参与者可能是对药物使用更感兴趣的人群,但针对普通人群的多个类似调查也显示了同样趋势。

英国剑桥大学神经系统科学家芭芭拉·萨哈基安认为,这项大规模调查结果揭示出,越来越多健康人群对这类药物使用是出于一种“生活方式”的选择,这引发了伦理方面的担忧。

此外,健康人群使用“聪明药”是否真的能更“聪明”还存在争议。有研究显示一些人在特定情况下用药有益处,如外科医生服用莫达非尼可以集中注意力,但对更广泛人群的研究表明这些药物不一定提高认知表现。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1717175, encodeId=8cf81e1717546, content=<a href='/topic/show?id=75c680843fe' target=_blank style='color:#2F92EE;'>#聪明药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80843, encryptionId=75c680843fe, topicName=聪明药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=436832361977, createdName=zutt, createdTime=Tue Sep 18 16:12:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615913, encodeId=cf4e1615913e7, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620849, encodeId=21721620849b6, content=<a href='/topic/show?id=9d858084092' target=_blank style='color:#2F92EE;'>#聪明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80840, encryptionId=9d858084092, topicName=聪明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316420160942, createdName=Boyinsh, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330720, encodeId=71c7330e2054, content=学习一下谢谢.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue Jul 10 23:54:02 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330697, encodeId=206f33069e03, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jul 10 22:38:31 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330684, encodeId=b35c330684fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jul 10 22:21:13 CST 2018, time=2018-07-10, status=1, ipAttribution=)]
    2018-09-18 zutt
  2. [GetPortalCommentsPageByObjectIdResponse(id=1717175, encodeId=8cf81e1717546, content=<a href='/topic/show?id=75c680843fe' target=_blank style='color:#2F92EE;'>#聪明药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80843, encryptionId=75c680843fe, topicName=聪明药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=436832361977, createdName=zutt, createdTime=Tue Sep 18 16:12:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615913, encodeId=cf4e1615913e7, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620849, encodeId=21721620849b6, content=<a href='/topic/show?id=9d858084092' target=_blank style='color:#2F92EE;'>#聪明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80840, encryptionId=9d858084092, topicName=聪明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316420160942, createdName=Boyinsh, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330720, encodeId=71c7330e2054, content=学习一下谢谢.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue Jul 10 23:54:02 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330697, encodeId=206f33069e03, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jul 10 22:38:31 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330684, encodeId=b35c330684fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jul 10 22:21:13 CST 2018, time=2018-07-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1717175, encodeId=8cf81e1717546, content=<a href='/topic/show?id=75c680843fe' target=_blank style='color:#2F92EE;'>#聪明药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80843, encryptionId=75c680843fe, topicName=聪明药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=436832361977, createdName=zutt, createdTime=Tue Sep 18 16:12:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615913, encodeId=cf4e1615913e7, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620849, encodeId=21721620849b6, content=<a href='/topic/show?id=9d858084092' target=_blank style='color:#2F92EE;'>#聪明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80840, encryptionId=9d858084092, topicName=聪明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316420160942, createdName=Boyinsh, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330720, encodeId=71c7330e2054, content=学习一下谢谢.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue Jul 10 23:54:02 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330697, encodeId=206f33069e03, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jul 10 22:38:31 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330684, encodeId=b35c330684fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jul 10 22:21:13 CST 2018, time=2018-07-10, status=1, ipAttribution=)]
    2018-07-12 Boyinsh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1717175, encodeId=8cf81e1717546, content=<a href='/topic/show?id=75c680843fe' target=_blank style='color:#2F92EE;'>#聪明药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80843, encryptionId=75c680843fe, topicName=聪明药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=436832361977, createdName=zutt, createdTime=Tue Sep 18 16:12:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615913, encodeId=cf4e1615913e7, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620849, encodeId=21721620849b6, content=<a href='/topic/show?id=9d858084092' target=_blank style='color:#2F92EE;'>#聪明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80840, encryptionId=9d858084092, topicName=聪明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316420160942, createdName=Boyinsh, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330720, encodeId=71c7330e2054, content=学习一下谢谢.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue Jul 10 23:54:02 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330697, encodeId=206f33069e03, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jul 10 22:38:31 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330684, encodeId=b35c330684fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jul 10 22:21:13 CST 2018, time=2018-07-10, status=1, ipAttribution=)]
    2018-07-10 changjiu

    学习一下谢谢.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1717175, encodeId=8cf81e1717546, content=<a href='/topic/show?id=75c680843fe' target=_blank style='color:#2F92EE;'>#聪明药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80843, encryptionId=75c680843fe, topicName=聪明药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=436832361977, createdName=zutt, createdTime=Tue Sep 18 16:12:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615913, encodeId=cf4e1615913e7, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620849, encodeId=21721620849b6, content=<a href='/topic/show?id=9d858084092' target=_blank style='color:#2F92EE;'>#聪明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80840, encryptionId=9d858084092, topicName=聪明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316420160942, createdName=Boyinsh, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330720, encodeId=71c7330e2054, content=学习一下谢谢.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue Jul 10 23:54:02 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330697, encodeId=206f33069e03, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jul 10 22:38:31 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330684, encodeId=b35c330684fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jul 10 22:21:13 CST 2018, time=2018-07-10, status=1, ipAttribution=)]
    2018-07-10 天地飞扬

    了解一下.谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1717175, encodeId=8cf81e1717546, content=<a href='/topic/show?id=75c680843fe' target=_blank style='color:#2F92EE;'>#聪明药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80843, encryptionId=75c680843fe, topicName=聪明药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=436832361977, createdName=zutt, createdTime=Tue Sep 18 16:12:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615913, encodeId=cf4e1615913e7, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620849, encodeId=21721620849b6, content=<a href='/topic/show?id=9d858084092' target=_blank style='color:#2F92EE;'>#聪明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80840, encryptionId=9d858084092, topicName=聪明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316420160942, createdName=Boyinsh, createdTime=Thu Jul 12 13:12:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330720, encodeId=71c7330e2054, content=学习一下谢谢.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Tue Jul 10 23:54:02 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330697, encodeId=206f33069e03, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jul 10 22:38:31 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330684, encodeId=b35c330684fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jul 10 22:21:13 CST 2018, time=2018-07-10, status=1, ipAttribution=)]
    2018-07-10 医者仁心5538

    学习了

    0

相关资讯

JAMA PSYCHIAT:利他林或可用于成瘾性疾病治疗

这一研究发表于近期《美国医学会杂志-精神病学》(JAMA Psychiatry.Published online June 26, 2013)。研究发现,盐酸哌甲酯(Methylphenidate,商品名:利他林)可调节大脑中某些特定通路的连接,而这些通路被认为与可卡因成瘾患者的自我控制及对药物的渴求有关。既往研究显示,口服盐酸哌甲酯可以改善可卡因成瘾患者的脑功能,这表现在某些特别的认知功能中,如

Nat Commun:药物“利他林”的副作用

药物“利他林”(利他能)中的活性成分Methylphenidate能增强大脑对进一步接触该药物的反应方式,同时在自行食用时还能增强大鼠寻找“安非他明”的行为。在本期Nature Communications上报告的这些发现揭示了也用于娱乐消遣目的的一种处方药隐藏的副作用。【原文下载】 在西方国家,Methylphenidate被普遍作为处方药用于治疗多动症(ADHD)和嗜睡症,但因其所报道的认知